Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

Christopher P. Denton; Peter A. Merkel; Daniel E. Furst; Dinesh Khanna; Paul Emery; Vivien M. Hsu; Nancy Silliman; James Streisand; John Powell; Anita Åkesson; John Coppock; Frank Van Den Hoogen; Ariane Herrick; Maureen D. Mayes; Douglas Veale; Joanna Haas; Stephen Ledbetter; Joseph H. Korn; Carol M. Black; James R. Seibold

doi:10.1002/art.22289

Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

Christopher P. Denton, Peter A. Merkel, Daniel E. Furst, Dinesh Khanna, Paul Emery, Vivien M. Hsu, Nancy Silliman, James Streisand, John Powell, Anita Åkesson, John Coppock, Frank Van Den Hoogen, Ariane Herrick, Maureen D. Mayes, Douglas Veale, Joanna Haas, Stephen Ledbetter, Joseph H. Korn, Carol M. Black, James R. Seibold

Research output: Contribution to journal › Article › peer-review

Abstract

Objective. To evaluate CAT-192, a recombinant human antibody that neutralizes transforming growth Factor β1 (TGFβ1), in the treatment of early-stage diffuse cutaneous systemic sclerosis (dcSSc). Methods. Patients with SSc duration of

Original language	English
Pages (from-to)	323-333
Number of pages	10
Journal	Arthritis Care & Research
Volume	56
Issue number	1
DOIs	https://doi.org/10.1002/art.22289
Publication status	Published - Jan 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/art.22289

Cite this

Denton, C. P., Merkel, P. A., Furst, D. E., Khanna, D., Emery, P., Hsu, V. M., Silliman, N., Streisand, J., Powell, J., Åkesson, A., Coppock, J., Van Den Hoogen, F., Herrick, A., Mayes, M. D., Veale, D., Haas, J., Ledbetter, S., Korn, J. H., Black, C. M., & Seibold, J. R. (2007). Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Care & Research, 56(1), 323-333. https://doi.org/10.1002/art.22289

@article{f08e0b1d154645c09e56310f95a0bccd,

title = "Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192",

abstract = "Objective. To evaluate CAT-192, a recombinant human antibody that neutralizes transforming growth Factor β1 (TGFβ1), in the treatment of early-stage diffuse cutaneous systemic sclerosis (dcSSc). Methods. Patients with SSc duration of",

author = "Denton, {Christopher P.} and Merkel, {Peter A.} and Furst, {Daniel E.} and Dinesh Khanna and Paul Emery and Hsu, {Vivien M.} and Nancy Silliman and James Streisand and John Powell and Anita {\AA}kesson and John Coppock and {Van Den Hoogen}, Frank and Ariane Herrick and Mayes, {Maureen D.} and Douglas Veale and Joanna Haas and Stephen Ledbetter and Korn, {Joseph H.} and Black, {Carol M.} and Seibold, {James R.}",

year = "2007",

month = jan,

doi = "10.1002/art.22289",

language = "English",

volume = "56",

pages = "323--333",

journal = "Arthritis Care & Research",

issn = "2151-464X",

publisher = "John Wiley & Sons Ltd",

number = "1",

}

Denton, CP, Merkel, PA, Furst, DE, Khanna, D, Emery, P, Hsu, VM, Silliman, N, Streisand, J, Powell, J, Åkesson, A, Coppock, J, Van Den Hoogen, F, Herrick, A, Mayes, MD, Veale, D, Haas, J, Ledbetter, S, Korn, JH, Black, CM & Seibold, JR 2007, 'Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192', Arthritis Care & Research, vol. 56, no. 1, pp. 323-333. https://doi.org/10.1002/art.22289

Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. / Denton, Christopher P.; Merkel, Peter A.; Furst, Daniel E. et al.
In: Arthritis Care & Research, Vol. 56, No. 1, 01.2007, p. 323-333.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

AU - Denton, Christopher P.

AU - Merkel, Peter A.

AU - Furst, Daniel E.

AU - Khanna, Dinesh

AU - Emery, Paul

AU - Hsu, Vivien M.

AU - Silliman, Nancy

AU - Streisand, James

AU - Powell, John

AU - Åkesson, Anita

AU - Coppock, John

AU - Van Den Hoogen, Frank

AU - Herrick, Ariane

AU - Mayes, Maureen D.

AU - Veale, Douglas

AU - Haas, Joanna

AU - Ledbetter, Stephen

AU - Korn, Joseph H.

AU - Black, Carol M.

AU - Seibold, James R.

PY - 2007/1

Y1 - 2007/1

N2 - Objective. To evaluate CAT-192, a recombinant human antibody that neutralizes transforming growth Factor β1 (TGFβ1), in the treatment of early-stage diffuse cutaneous systemic sclerosis (dcSSc). Methods. Patients with SSc duration of

AB - Objective. To evaluate CAT-192, a recombinant human antibody that neutralizes transforming growth Factor β1 (TGFβ1), in the treatment of early-stage diffuse cutaneous systemic sclerosis (dcSSc). Methods. Patients with SSc duration of

U2 - 10.1002/art.22289

DO - 10.1002/art.22289

M3 - Article

SN - 2151-464X

VL - 56

SP - 323

EP - 333

JO - Arthritis Care & Research

JF - Arthritis Care & Research

IS - 1

ER -

Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this